Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Expression of SART3 tumor-rejection antigen in gastric cancers.

Literature DB >> 10760694

Expression of SART3 tumor-rejection antigen in gastric cancers.

F Niiya¹, S Nishizaka, K Matsunaga, K Koufuji, M Mori, H Katai, H Yamana, K Itoh.

Abstract

We previously reported SART3 as a tumor-rejection antigen recognized by histocompatibility leukocyte antigen (HLA)-A24-restricted cytotoxic T lymphocytes (CTLs). In this study, we investigated the expression of the SART3 antigen in gastric cancers, as a candidate for use in specific immunotherapy. The SART3 antigen was detected in 9 of 10 (90%) gastric cancer cell lines, 35 of 52 (67.3%) gastric cancer tissues, and 0 of 20 non-tumorous gastric tissues. SART3-derived peptides corresponding to positions 109- 118 and 315-323 induced HLA-A24-restricted and tumor-specific CTLs from peripheral blood mononuclear cells (PBMCs) of gastric cancer patients. These peptide-induced CTLs recognized HLA-A24(+) SART3(+) gastric cancer cells, but not HLA-A24(+) SART3(-) or HLA-A24(-) SART3(+) gastric cancer cells. Therefore, the SART3 peptides could be useful in specific immunotherapy of gastric cancer patients.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Antigens, Neoplasm

Year: 2000 PMID： 10760694 PMCID： PMC5926363 DOI： 10.1111/j.1349-7006.2000.tb00950.x

Source DB: PubMed Journal: Jpn J Cancer Res ISSN： 0910-5050

14 in total

1. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.

Authors: M Marchand; N van Baren; P Weynants; V Brichard; B Dréno; M H Tessier; E Rankin; G Parmiani; F Arienti; Y Humblet; A Bourlond; R Vanwijck; D Liénard; M Beauduin; P Y Dietrich; V Russo; J Kerger; G Masucci; E Jäger; J De Greve; J Atzpodien; F Brasseur; P G Coulie; P van der Bruggen; T Boon
Journal: Int J Cancer Date: 1999-01-18 Impact factor: 7.396

2. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors: S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal: Nat Med Date: 1998-03 Impact factor: 53.440

3. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer.

Authors: T Hoshino; N Seki; M Kikuchi; T Kuramoto; O Iwamoto; I Kodama; K Koufuji; J Takeda; K Itoh
Journal: Int J Cancer Date: 1997-03-17 Impact factor: 7.396

4. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.

Authors: D Yang; M Nakao; S Shichijo; T Sasatomi; H Takasu; H Matsumoto; K Mori; A Hayashi; H Yamana; K Shirouzu; K Itoh
Journal: Cancer Res Date: 1999-08-15 Impact factor: 12.701

5. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes.

Authors: H Inoue; M Mori; J Li; K Mimori; M Honda; H Nakashima; K Mafune; Y Tanaka; T Akiyoshi
Journal: Int J Cancer Date: 1995-11-15 Impact factor: 7.396

6. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors: P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal: Science Date: 1991-12-13 Impact factor: 47.728

7. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.

Authors: K Kono; Y Rongcun; J Charo; F Ichihara; E Celis; A Sette; E Appella; T Sekikawa; Y Matsumoto; R Kiessling
Journal: Int J Cancer Date: 1998-10-05 Impact factor: 7.396

8. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Authors: P F Robbins; M El-Gamil; Y F Li; Y Kawakami; D Loftus; E Appella; S A Rosenberg
Journal: J Exp Med Date: 1996-03-01 Impact factor: 14.307

9. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

Authors: B Gaugler; B Van den Eynde; P van der Bruggen; P Romero; J J Gaforio; E De Plaen; B Lethé; F Brasseur; T Boon
Journal: J Exp Med Date: 1994-03-01 Impact factor: 14.307

10. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors: C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal: J Exp Med Date: 1992-11-01 Impact factor: 14.307

6 in total

1. Tip110 Regulates the Cross Talk between p53 and Hypoxia-Inducible Factor 1α under Hypoxia and Promotes Survival of Cancer Cells.

Authors: Khalid Amine Timani; Ying Liu; Yan Fan; Khalid S Mohammad; Johnny J He
Journal: Mol Cell Biol Date: 2015-05-04 Impact factor: 4.272

6. Characterization of gastric adenocarcinoma cell lines established from CEA424/SV40 T antigen-transgenic mice with or without a human CEA transgene.

Authors: Jessica Nöckel; Natasja K van den Engel; Hauke Winter; Rudolf A Hatz; Wolfgang Zimmermann; Robert Kammerer
Journal: BMC Cancer Date: 2006-03-14 Impact factor: 4.430